Although previous relevant meta-analyses showed that SGLT2 inhibitors have a neutral effect on the risk of stroke5–8, these randomized controlled trials (RCTs) focused on statistical analysis of non-fatal strokes from cardiovascular events without distinguishing between the different stroke subtypes, such as fatal, transient ischemic attack (TIA), ischemic and hemorrhagic. Here, SLC5A2 is linked to transient ischemic attack.